Novartis agrees to buy Avidity Biosciences
MLex Summary: Swiss drugmaker Novartis announced that it has agreed to buy Avidity Biosciences, a biopharmaceutical firm focused on rare diseases, for $12 billion. The companies expect the merger to close...To view the full article, register now.
Already a subscriber? Click here to view full article